| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 320/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Lamotrigine is a novel phenyltriazine antiepileptic drug that was launched in China in 2005. Its mechanism of action is to block presynaptic membrane voltage-gated sodium channels and inhibit pathological glutamate release, thereby suppressing glutamate induced action potential bursts and stabilizing neuronal cell membranes. As a broad-spectrum antiepileptic drug, lamotrigine is mainly used as monotherapy or adjuvant therapy for partial and systemic epileptic seizures in clinical practice, and can also be used as an emotional stabilizer to treat type I bipolar disorder.
Lamotrigine is a voltage dependent sodium channel blocker, and its main mechanism of action against epilepsy is: Inhibiting voltage dependent type IIa Na+channels, stabilizing fine cell membranes, and inhibiting abnormal neuronal discharges; Stabilize the presynaptic membrane and inhibit the release of excitatory neurotransmitters, especially glutamate; Inhibit voltage-gated calcium channels.
| Product name | Lamotrigine |
| Appearance | white Powder |
| Specification | 99% |
| Shelf life | 2 years when properly stored |
Function and Application
Lamotrigine is a phenyltriazine antiepileptic drug. It is used to treat epilepsy and as an emotional stabilizer for bipolar disorder. Lamotrigine is the first drug approved by the US Food and Drug Administration (FDA) for the maintenance of type I bipolar disorder treatment since lithium was approved. It has been approved for use in over 30 countries.
Lamotrigine has relatively few side effects and does not require laboratory monitoring. Although it is suitable for epilepsy and bipolar disorder, there is evidence to suggest that lamotrigine may have some clinical efficacy in certain neuropathic pain states.
Lamotrigine is a second-generation antiepileptic drug (AED) used in the United Kingdom and the United States as lamotrigine ® Known for its proprietary brand name of GlaxoSmithKline, Brentford.
It is mainly used for partial epilepsy, especially for refractory partial epilepsy that cannot be controlled by other monotherapy or combination therapy. Its effect is safe and effective. About 50% of patients with seizures, atypical seizures, and myoclonic seizures are under control. It is also suitable as an adjuvant drug for the treatment of Lennox Gastant syndrome in refractory epilepsy, as well as secondary and idiopathic generalized tonic clonic seizures.
){kind=link}